Literature DB >> 28858441

The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction: Validation in Patients With Major Depressive Disorder.

Roger S McIntyre1,2,3,4,5,6, Michael W Best7, Christopher R Bowie7,8, Nicole E Carmona2, Danielle S Cha2,9, Yena Lee2,6, Mehala Subramaniapillai2, Rodrigo B Mansur2, Harry Barry10, Bernhard T Baune11, Larry Culpepper12, Philippe Fossati13, Tracy L Greer14, Catherine Harmer15, Esther Klag16, Raymond W Lam17, Hans-Ulrich Wittchen18, John Harrison19,20,21.   

Abstract

OBJECTIVE: To validate the THINC-integrated tool (THINC-it)-a freely available, patient-administered, computerized screening tool integrating subjective and objective measures of cognitive function in adults with major depressive disorder (MDD).
METHODS: Subjects aged 18 to 65 years (n = 100) with recurrent MDD experiencing a major depressive episode of at least moderate severity were evaluated and compared to age-, sex-, and education-matched healthy controls (n = 100). Between January and June 2016, subjects completed the THINC-it, which includes variants of the Choice Reaction Time Identification Task (IDN), One-Back Test, Digit Symbol Substitution Test, Trail Making Test-Part B, and the Perceived Deficits Questionnaire for Depression-5-item (PDQ-5-D).
RESULTS: The THINC-it required approximately 10 to 15 minutes for administration and was capable of detecting cognitive deficits in adults with MDD. A total of 44.4% of adults with MDD exhibited cognitive performance at ≥ 1.0 SD below that of healthy controls on standardized mean scores of the THINC-it. Concurrent validity of the overall tool, based on a calculated composite score, was acceptable (r = 0.539, P < .001). Concurrent validity of the component tests ranged from -0.083 (IDN) to 0.929 (PDQ-5-D). Qualitative survey results indicated that there was a high level of satisfaction and perceived value in administering the THINC-it regarding its impact on the appropriateness and quality of care being received.
CONCLUSIONS: The THINC-it is a valid and sensitive tool for detecting cognitive dysfunction in adults with MDD that is free, easy to use, and rapidly administered. The THINC-it should be incorporated into the assessment and measurement of all patients with MDD, particularly among those with enduring functional impairment. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02508493. © Copyright 2017 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2017        PMID: 28858441     DOI: 10.4088/JCP.16m11329

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  22 in total

1.  International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic).

Authors:  Takahiro Soda; Declan M McLoughlin; Scott R Clark; Leif Oltedal; Ute Kessler; Jan Haavik; Chad Bousman; Daniel J Smith; Miquel Bioque; Caitlin C Clements; Colleen Loo; Fidel Vila-Rodriguez; Alessandra Minelli; Brian J Mickey; Roumen Milev; Anna R Docherty; Julie Langan Martin; Eric D Achtyes; Volker Arolt; Ronny Redlich; Udo Dannlowski; Narcis Cardoner; Emily Clare; Nick Craddock; Arianna Di Florio; Monika Dmitrzak-Weglarz; Liz Forty; Katherine Gordon-Smith; Mustafa Husain; Wendy M Ingram; Lisa Jones; Ian Jones; Mario Juruena; George Kirov; Mikael Landén; Daniel J Müller; Axel Nordensköld; Erik Pålsson; Meethu Paul; Agnieszka Permoda; Bartlomiej Pliszka; Jamie Rea; Klaus O Schubert; Joshua A Sonnen; Virginia Soria; Will Stageman; Akihiro Takamiya; Mikel Urretavizacaya; Stuart Watson; Maxim Zavorotny; Allan H Young; Eduard Vieta; Janusz K Rybakowski; Massimo Gennarelli; Peter P Zandi; Patrick F Sullivan; Bernhard T Baune
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-12-04       Impact factor: 5.270

2.  The THINC-it Tool for Cognitive Assessment and Measurement in Major Depressive Disorder: Sensitivity to Change.

Authors:  Roger S McIntyre; Mehala Subramaniapillai; Caroline Park; Hannah Zuckerman; Bing Cao; Yena Lee; Michelle Iacobucci; Flora Nasri; Dominika Fus; Christopher R Bowie; Tanya Tran; Joshua D Rosenblat; Rodrigo B Mansur
Journal:  Front Psychiatry       Date:  2020-06-24       Impact factor: 4.157

Review 3.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

4.  The clinical characterization of the adult patient with depression aimed at personalization of management.

Authors:  Mario Maj; Dan J Stein; Gordon Parker; Mark Zimmerman; Giovanni A Fava; Marc De Hert; Koen Demyttenaere; Roger S McIntyre; Thomas Widiger; Hans-Ulrich Wittchen
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

5.  Conducting clinical studies targeting cognition in psychiatry: guiding principles and design.

Authors:  Tamsyn E Van Rheenen; Kathryn E Lewandowski; Jessica M Lipschitz; Katherine E Burdick
Journal:  CNS Spectr       Date:  2018-09-24       Impact factor: 3.790

Review 6.  Digit Symbol Substitution Test: The Case for Sensitivity Over Specificity in Neuropsychological Testing.

Authors:  Judith Jaeger
Journal:  J Clin Psychopharmacol       Date:  2018-10       Impact factor: 3.153

7.  Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.

Authors:  Célia Fourrier; Emma Sampson; Natalie T Mills; Bernhard T Baune
Journal:  Trials       Date:  2018-08-20       Impact factor: 2.279

8.  Assessment of current clinical practices for major depression in Japan using a web-based questionnaire.

Authors:  Hikaru Hori; Kentaro Yamato
Journal:  Neuropsychiatr Dis Treat       Date:  2019-10-01       Impact factor: 2.570

Review 9.  Assessment and Management of Cognitive and Psychosocial Dysfunctions in Patients With Major Depressive Disorder: A Clinical Review.

Authors:  Andrea Fiorillo; Bernardo Carpiniello; Serafino De Giorgi; Silvestro La Pia; Giuseppe Maina; Gaia Sampogna; Edoardo Spina; Alfonso Tortorella; Antonio Vita
Journal:  Front Psychiatry       Date:  2018-10-11       Impact factor: 4.157

10.  Stability, reliability, and validity of the THINC-it screening tool for cognitive impairment in depression: A psychometric exploration in healthy volunteers.

Authors:  John E Harrison; Harry Barry; Bernhard T Baune; Michael W Best; Christopher R Bowie; Danielle S Cha; Larry Culpepper; Philippe Fossati; Tracy L Greer; Catherine Harmer; Esther Klag; Raymond W Lam; Yena Lee; Rodrigo B Mansur; Hans-Ulrich Wittchen; Roger S McIntyre
Journal:  Int J Methods Psychiatr Res       Date:  2018-08-07       Impact factor: 4.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.